[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial
Koh E, Gan H, Senko C, Francis R, Ebert M, Lee S, Lau E, Khasraw M, Nowak A, Bailey D, Moffat B, Fitt G, Hicks R, Coffey R, Verhaak R, Walsh K, Barnes E, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas P, Roach P, Back M, Leonard R, Scott A. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. BMJ Open 2023, 13: e071327. PMID: 37541751, PMCID: PMC10407346, DOI: 10.1136/bmjopen-2022-071327.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAustraliaBrain NeoplasmsClinical Trials, Phase II as TopicFicusGlioblastomaHumansMagnetic Resonance ImagingMulticenter Studies as TopicNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyPositron-Emission TomographyProspective StudiesTyrosineConceptsFET PETPositron emission tomographyPrimary central nervous system cancerTumor progressionCentral nervous system cancerL-tyrosine positron emission tomographyFET-PET imagingPhase II studyCo-primary outcomesProgression-free survivalMaximal safe resectionPost-chemotherapy treatmentNervous system cancersHealth economic impactHuman Research Ethics CommitteePatterns of failureTrue tumor progressionGood clinical practiceDeclaration of HelsinkiRadiological progressionConcurrent chemoradiationInitial surgeryPostoperative radiotherapyII studyOverall survival